×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
HCM – hutchmed (china) limited - american depositary shares (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
HCM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/13
11:00 pm
hcm
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
Low
Report
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
1/6
07:00 pm
hcm
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
Medium
Report
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
1/4
07:00 pm
hcm
HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma
Low
Report
HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma
12/30
05:00 am
hcm
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification
Low
Report
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification
12/29
05:20 am
hcm
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma [Yahoo! Finance]
Low
Report
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma [Yahoo! Finance]
12/29
03:35 am
hcm
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma
Low
Report
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma
12/16
07:00 pm
hcm
HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors
Low
Report
HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors
12/7
07:00 pm
hcm
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China
Low
Report
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/14
06:06 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Jan 14
Low
Report
Form 6-K HUTCHMED (China) Ltd For: Jan 14
1/7
06:05 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Jan 07
Medium
Report
Form 6-K HUTCHMED (China) Ltd For: Jan 07
1/5
06:06 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Jan 05
Low
Report
Form 6-K HUTCHMED (China) Ltd For: Jan 05
12/31
06:11 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Dec 31
Low
Report
Form 6-K HUTCHMED (China) Ltd For: Dec 31
12/30
06:04 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Dec 30
Low
Report
Form 6-K HUTCHMED (China) Ltd For: Dec 30
12/29
06:08 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Dec 29
Low
Report
Form 6-K HUTCHMED (China) Ltd For: Dec 29
12/17
06:05 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Dec 17
Low
Report
Form 6-K HUTCHMED (China) Ltd For: Dec 17
12/8
06:19 am
hcm
Form 6-K HUTCHMED (China) Ltd For: Dec 08
Low
Report
Form 6-K HUTCHMED (China) Ltd For: Dec 08
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/13
HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating.
10.3%
10/11 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.0%
4/22 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.2%
9/30 CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term 4.9%
2/6 Chi-Med Announces the Exercise of Underwriters’ Over-allotment Option for Public Offering of ADSs 3.8%
7/30 Hutchison China MediTech Limited 2019 Q2 - Results - Earnings Call Slides [Seeking Alpha] 3.2%
4/17 Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors 3.1%
10/23 HUTCHISON CHINA/S (NASDAQ: HCM) is now covered by analysts at Bank of America Corp. They set a "buy" rating on the stock. 3.1%
1/13 Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors 2.9%
3/3 Hutchison China MediTech Limited (HCM) Q4 2019 Earnings Call Transcript [The Motley Fool] 2.9%
10/11 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.0%
4/22 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.2%
9/30 CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term 4.9%
2/6 Chi-Med Announces the Exercise of Underwriters’ Over-allotment Option for Public Offering of ADSs 3.8%
7/30 Hutchison China MediTech Limited 2019 Q2 - Results - Earnings Call Slides [Seeking Alpha] 3.2%
4/17 Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors 3.1%
10/23 HUTCHISON CHINA/S (NASDAQ: HCM) is now covered by analysts at Bank of America Corp. They set a "buy" rating on the stock. 3.1%
1/13 Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors 2.9%
3/3 Hutchison China MediTech Limited (HCM) Q4 2019 Earnings Call Transcript [The Motley Fool] 2.9%
TOP News Decliners
6/27
Chi-Med Announces Secondary Offering of American Depositary Shares
-18.8%
3/18 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -17.4%
1/21 Chi-Med Announces Proposed Public Offering of ADSs -12.6%
1/23 Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs -9.8%
7/20 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -7.7%
9/3 Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma -5.3%
12/30 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -3.4%
2/25 Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 – adjustment to announcement and presentation logistics due to travel restrictions -3.3%
9/27 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -2.9%
6/14 Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early -2.7%
3/18 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -17.4%
1/21 Chi-Med Announces Proposed Public Offering of ADSs -12.6%
1/23 Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs -9.8%
7/20 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -7.7%
9/3 Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma -5.3%
12/30 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -3.4%
2/25 Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 – adjustment to announcement and presentation logistics due to travel restrictions -3.3%
9/27 HUTCHISON CHINA/S (NASDAQ: HCM) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -2.9%
6/14 Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early -2.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: